Project

A phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Amyloid Depleter ALXN2220 in adult participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Scheduled · 2024 until 2029

Ehl Niklas, Vetsch Susanne